Semaglutide

Neonatal medical care

id	Study   Auto Kolding (Controls exposed to insulin), 2025Kolding (Controls unexposed, general pop), 2025	Lib. in paper	Exposition period  Auto during pregnancy (anytime or not specified)1st trimester2nd trimester3rd trimester2nd and/or 3rd trimesterthroughout pregnancyearly pregnancydays before deliverylate pregnancypreconception-onlypericonceptionalpreconceptional for kinetic reasonat least 1st trimester3 months (or more) before pregnancy or during pregnancy1st and 2nd trimester3 months or more before pregnancy or1st trimesterPaternal exp. genotoxic window only (0–3 months preconception)Paternal exposure: epigenetic window only (3–xxx months preconception)Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception)Paternal exposure: other window	Study type  All studies Case control excluded Only case control	Control type    Auto unexposed (general population or NOS)unexposed, sickunexposed, disease freeexposed to other treatment, sicknot specifiedsiblingwhatever (meta-analysis)	Tags	OR 95%CI	x1/n1 x0/n0	no cases	no exposed	ROB	Ref.
S18830 R80185	Kolding (Controls exposed to insulin), 2025	Respiratory distress syndrome	1st trimester	retrospective cohort	exposed to other treatment, sick excluded	Adjustment: No GLP1-RA indication: Mixed (Diabetes and/or Overweight) or Unspecified	1.18 [0.22;4.08] excluded (control group)	3/29   46/517	49	29		ref
S18831 R80192	Kolding (Controls unexposed, general pop), 2025	Respiratory distress syndrome	1st trimester excluded	retrospective cohort	unexposed (general population or NOS)	Adjustment: No GLP1-RA indication: Mixed (Diabetes and/or Overweight) or Unspecified	4.70 [0.91;15.34] excluded (exposition period)	3/29   2,408/100,448	2,411	29		ref
					Total	0 studies	NaN [NaN;NaN]		0	0
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

Sensitivity analysis